Srdan Verstovsek

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
    Srdan Verstovsek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:1202-9. 2012
  2. pmc Ruxolitinib for the treatment of myelofibrosis: its clinical potential
    Alen Ostojic
    Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia
    Ther Clin Risk Manag 8:95-103. 2012
  3. ncbi request reprint Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
    Srdan Verstovsek
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Leuk Res 38:316-22. 2014
  4. pmc Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
    Srdan Verstovsek
    Haematologica 98:1865-71. 2013
  5. pmc The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
    Srdan Verstovsek
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 161:508-16. 2013
  6. pmc Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Haematol 90:89-98. 2013
  7. ncbi request reprint Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis
    Srdan Verstovsek
    Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Postgrad Med 125:128-35. 2013
  8. pmc Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib
    J Mascarenhas
    Mount Sinai School of Medicine, NY, USA
    Curr Med Chem 19:4399-413. 2012
  9. ncbi request reprint JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
    Fabio P S Santos
    Hematology and Stem Cell Transplantation, Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil
    Anticancer Agents Med Chem 12:1098-109. 2012
  10. pmc Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
    Jasleen Randhawa
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Hematol Oncol 5:43. 2012

Collaborators

Detail Information

Publications115 found, 100 shown here

  1. ncbi request reprint Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
    Srdan Verstovsek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:1202-9. 2012
    ....
  2. pmc Ruxolitinib for the treatment of myelofibrosis: its clinical potential
    Alen Ostojic
    Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia
    Ther Clin Risk Manag 8:95-103. 2012
    ..Longer follow-up of the phase III MF studies is needed to reach firm conclusions regarding ruxolitinib's capacity to modify the natural disease course...
  3. ncbi request reprint Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
    Srdan Verstovsek
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Leuk Res 38:316-22. 2014
    ..Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21 h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients...
  4. pmc Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
    Srdan Verstovsek
    Haematologica 98:1865-71. 2013
    ..These data indicate that ruxolitinib treatment provides durable reductions in spleen volume and improvements in quality of life and suggest a continued survival advantage for ruxolitinib over placebo. ..
  5. pmc The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
    Srdan Verstovsek
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 161:508-16. 2013
    ....
  6. pmc Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Haematol 90:89-98. 2013
    ..This review discusses the diagnosis and management of patients with advanced SM, including the relevance of KIT in this disease, potential therapies targeting this kinase, and criteria for measuring responses to these therapies...
  7. ncbi request reprint Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis
    Srdan Verstovsek
    Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Postgrad Med 125:128-35. 2013
    ..Thrombocytopenia and anemia were the most common adverse events with treatment. Ongoing trials are assessing the efficacy and safety of ruxolitinib therapy in patients with PV and ET...
  8. pmc Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib
    J Mascarenhas
    Mount Sinai School of Medicine, NY, USA
    Curr Med Chem 19:4399-413. 2012
    ..The most common adverse events were anemia and thrombocytopenia, which were manageable and rarely led to discontinuation. This review addresses the cellular and molecular biology, and the clinical management of MPN...
  9. ncbi request reprint JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
    Fabio P S Santos
    Hematology and Stem Cell Transplantation, Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil
    Anticancer Agents Med Chem 12:1098-109. 2012
    ..In this article, we review the current state of JAK2 inhibitors and discuss why these drugs could be a valuable addition to the treatment armamentarium for patients with and without the JAK2V617F mutation...
  10. pmc Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
    Jasleen Randhawa
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Hematol Oncol 5:43. 2012
    ..This review discusses current therapeutic options for splenomegaly associated with primary or secondary MF and the treatment potential of the JAK inhibitors in this setting...
  11. ncbi request reprint The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells
    Xiaodong Cheng
    Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Anticancer Res 32:2871-80. 2012
    ..These results indicate that GMZ27 induces apoptosis in AML cells in a PML-RARα-independent fashion, through the induction of ROS production. This activity provides the rationale for the testing of GMZ27 in patients with AML...
  12. ncbi request reprint A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    Srdan Verstovsek
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 366:799-807. 2012
    ..Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis...
  13. doi request reprint Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:368-73. 2009
    ..Patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that are refractory to standard therapies are difficult to manage and have significantly shortened life expectancy...
  14. ncbi request reprint Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
    Srdan Verstovsek
    Leukemia Department, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:3906-15. 2008
    ....
  15. ncbi request reprint Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Leuk Res 30:1499-505. 2006
    ..In addition, both drugs inhibited the phosphorylation of PDGFR-alpha tyrosine kinase with equivalent efficacy. We conclude that AMN107 and imatinib are active and equipotent against cells expressing the FIP1L1-PDGFR-alpha fusion gene...
  16. ncbi request reprint Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
    Srdan Verstovsek
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, United States
    Leuk Res 30:1365-70. 2006
    ....
  17. ncbi request reprint Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders
    Srdan Verstovsek
    Leukemia Department, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Res 33:617-23. 2009
    ..This review presents emerging data on the preclinical and clinical activity of dasatinib in these diseases, which suggest that larger clinical studies are warranted...
  18. ncbi request reprint Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis
    Srdan Verstovsek
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:1988-96. 2010
    ....
  19. doi request reprint Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Srdan Verstovsek
    M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 363:1117-27. 2010
    ..INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor...
  20. ncbi request reprint Ruxolitinib for the treatment of myelofibrosis
    A Ostojic
    Department of Hematology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia
    Drugs Today (Barc) 47:817-27. 2011
    ..Low toxicity, alleviation of constitutional symptoms, weight gain and improvement in general physical condition were observed with ruxolitinib treatment which may substantially improve quality of life in patients with myelofibrosis...
  21. ncbi request reprint Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Srdan Verstovsek
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Hematol Oncol 24:181-8. 2006
    ....
  22. ncbi request reprint Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  23. doi request reprint Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2232-5. 2009
    ..P190(BCR-ABL) CML is rare and is associated with an inferior outcome to therapy with TKI. These patients need to be identified as high-risk patients...
  24. ncbi request reprint Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells
    Nada Orsolic
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Sci 97:952-60. 2006
    ..In conclusion, adaphostin showed significant and selective activity against CML and AML cells and its development for clinical testing is warranted...
  25. ncbi request reprint Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2099-108. 2005
    ..The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience...
  26. ncbi request reprint Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  27. ncbi request reprint The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation
    Taghi Manshouri
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Sci 99:1265-73. 2008
    ..Flow cytometric analysis of expanded PV progenitor cells treated with CP-690,550 suggests a possible transition towards a pattern of erythroid differentiation resembling expanded cells from normal healthy controls...
  28. ncbi request reprint Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  29. ncbi request reprint Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  30. ncbi request reprint Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Jorge Cortes
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3425-32. 2005
    ..To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib...
  31. pmc Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
    Naveen Pemmaraju
    Department of Leukemia, University of Texas, Anderson Cancer Center, Houston, TX 77230, USA
    Haematologica 97:1029-35. 2012
    ..Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients...
  32. ncbi request reprint EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
    Jingxuan Pan
    The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 109:315-22. 2007
    ..We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KIT-driven malignancies harboring active site mutations...
  33. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  34. ncbi request reprint Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  35. doi request reprint MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells
    Mirna Golemovic
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Invest New Drugs 28:402-12. 2010
    ..This agent, therefore, combines low in vivo toxicity with formidable in vitro pro-apoptotic ROS-mediated activity, and may represent a novel OAD suitable for clinical development against a variety of hematological malignancies...
  36. ncbi request reprint Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  37. pmc Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
    ..Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation...
  38. ncbi request reprint Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  39. ncbi request reprint Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2154-60. 2009
    ..In conclusion, imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetic failure and a previous cytogenetic response to standard-dose imatinib...
  40. ncbi request reprint Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  41. ncbi request reprint Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  42. ncbi request reprint AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    Mirna Golemovic
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:4941-7. 2005
    ..These results strongly support investigation of the clinical efficacy of AMN107 in patients with CML...
  43. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  44. doi request reprint Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Constantine S Tam
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:5587-93. 2009
    ..We aimed to define an accelerated phase (AP) in MF by characterizing disease features that can identify patients with median overall survival of <or= 12 months at any time in the disease course...
  45. ncbi request reprint Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  46. ncbi request reprint Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  47. ncbi request reprint A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  48. pmc A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  49. pmc Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3880-9. 2010
    ....
  50. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  51. ncbi request reprint Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1430-7. 2003
    ..The objective of the current study was to evaluate the benefit of adding imatinib to the treatment sequence of patients with early chronic phase Ph-positive CML who received interferon alpha (IFN)-based regimens as frontline therapy...
  52. ncbi request reprint Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  53. ncbi request reprint Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
    Roberto H Nussenzveig
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Hematol 90:58-63. 2009
    ..46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV...
  54. ncbi request reprint Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:899-906. 2007
    ..A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)...
  55. ncbi request reprint Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
    Nada Orsolic
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030 4009, USA
    Br J Haematol 124:727-38. 2004
    ..These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted...
  56. ncbi request reprint AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
    Srdan Verstovsek
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 104:1230-6. 2005
    ..Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response...
  57. ncbi request reprint Activity of alemtuzumab in patients with CD52-positive acute leukemia
    Raoul Tibes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2645-51. 2006
    ..Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)...
  58. ncbi request reprint Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:661-9. 2003
    ..In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML...
  59. doi request reprint Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  60. ncbi request reprint Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4760-6. 2009
    ..To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF)...
  61. ncbi request reprint Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  62. ncbi request reprint Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha
    Jorge Cortes
    Department of Leukemia and Bioimmunotherapy, M D Anderson Cancer Center, University of Texas Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:83-6. 2003
    ..In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission...
  63. ncbi request reprint Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1295-302. 2007
    ..Lonafarnib can inhibit the proliferation of imatinib-resistant cells and increases imatinib-induced apoptosis in vitro in cells from imatinib-resistant patients...
  64. ncbi request reprint Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  65. ncbi request reprint Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
    Bryan Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 77:209-14. 2004
    ..SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed...
  66. ncbi request reprint Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  67. ncbi request reprint The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
    Simona Gatto
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Haematologica 88:853-63. 2003
    ..We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction...
  68. ncbi request reprint Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  69. doi request reprint WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:788-96. 2008
    ..However, no effective JAK2 inhibitors are currently available for clinical use...
  70. doi request reprint Clofarabine combinations as acute myeloid leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2090-6. 2008
    ..Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine...
  71. doi request reprint Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:572-80. 2011
    ..Interferon alpha (IFN α) is efficacious in CML likely due to its immunomodulatory properties, and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor (GM-CSF)...
  72. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  73. ncbi request reprint Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  74. ncbi request reprint Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  75. ncbi request reprint A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  76. ncbi request reprint Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007
    ..CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone...
  77. ncbi request reprint The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  78. ncbi request reprint Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line
    Clara Ricci
    Department of Leukemia, Division of Medicine, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 62:5995-8. 2002
    ..Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial. No other mutations were identified in the kinase domain of the BCR/ABL gene...
  79. ncbi request reprint Experimental therapy in myelofibrosis with myeloid metaplasia
    Srdan Verstovsek
    The University of Texas, Department of Leukemia, MD Anderson Cancer Center, USA
    Expert Opin Investig Drugs 15:1555-63. 2006
    ..This article reviews the current status of experimental novel therapies for MMM...
  80. ncbi request reprint Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML
    Elihu Estey
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Leuk Res 27:475-9. 2003
    ..These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000...
  81. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  82. ncbi request reprint In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
    Barbara Scappini
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:2653-62. 2002
    ..In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML...
  83. ncbi request reprint Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
    Jingxuan Pan
    Department of Leukemia, The University of Texas, Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Sci 98:1223-5. 2007
    ..In contrast, neither drug was effective against HMC-1.2 cells at the dose range tested. The present results suggest clinical potential for INNO-406 in KIT V560G-expressing malignancies...
  84. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  85. ncbi request reprint Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein
    Barbara Scappini
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1459-71. 2004
    ....
  86. doi request reprint Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Leuk Res 33:1481-4. 2009
    ..Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM...
  87. ncbi request reprint Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
    Sameer A Parikh
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:269-74. 2010
    ..Grade 1-3 diarrhea, mucositis, and neutropenia were the most common adverse effects. No Grade 4 toxicity was noted. In conclusion, everolimus does not result in appreciable clinical activity in patients with SM...
  88. pmc Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 115:3109-17. 2010
    ..Preliminary clinical results support these preclinical data and establish INCB018424 as a promising oral agent for the treatment of MPNs...
  89. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  90. ncbi request reprint Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 105:2281-6. 2005
    ..We conclude that treatment with imatinib mesylate overcomes the adverse prognostic significance of der(9) deletions in patients with CML...
  91. doi request reprint New JAK2 inhibitors for myeloproliferative neoplasms
    Alfonso Quintas-Cardama
    UT MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA
    Expert Opin Investig Drugs 20:961-72. 2011
    ..More importantly, the demonstration of constitutive kinase activity emanating from the JAK2 protein provided the rationale for the development of small-molecule JAK2 kinase inhibitors...
  92. pmc Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
    ..In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks...
  93. ncbi request reprint Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  94. doi request reprint The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
    Constantine S Tam
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:4171-8. 2009
    ..Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated...
  95. ncbi request reprint Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2212-7. 2003
    ..The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown...
  96. ncbi request reprint Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 9616, USA
    Clin Lymphoma Myeloma Leuk 11:54-9. 2011
    ..Myelosuppression-associated complications were frequent. Pegaspargase was equally effective and easier to administer than L-asparaginase. Augmented hyper-CVAD may be suitable to be studied in younger adults with untreated ALL...
  97. ncbi request reprint Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:3097-9. 2003
    ..0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML...
  98. ncbi request reprint Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 106:1306-15. 2006
    ....
  99. pmc Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Gautam Borthakur
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 96:62-8. 2011
    ..A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...